Idiopathic Pulmonary Fibrosis Disease Treatment: Global Markets
The current report provides detailed coverage of IPF. This report will provide perspective on the drugs and therapies used for the management of IPF, including forecast trends and sales through 2024. Important manufacturers, technologies and factors influencing demand are discussed.
The market has been segregated geographically into the U.S., Japan and five major European markets (Germany, France, Italy, Spain, and the U.K.). For market estimates, data has been provided for the year 2018 as the base year, 2019 and then forecast for 2024.
- An overview of the global markets for idiopathic pulmonary fibrosis (IPF) disease treatment
- Analyses of the global market trends, with corresponding market analysis data for 2018 and 2019, and projections of compound annual growth rates (CAGRs) through 2024
- Estimation of market size and market share analysis of IPF chronic disease on the basis of type of therapeutics and geography
- Insights into the market trends and opportunities, drivers and restraints, regulatory framework, epidemiology, complications, and prevalence of this chronic lung disease
- Company profiles of the market leading participants within the pharmaceuticals industry
Table of Contents Chapter 1 Introduction Reasons for Doing this Study Scope of Report Information Sources Methodology Analyst's Credentials Related BCC Research Reports Chapter 2 Summary and Highlights Chapter 3 Drug Development and Approval Process Introduction Drug Discovery Process Drug Definition Drug Development Regulations Classification of Techniques Used in Drug Discovery High-Throughput Screening Bioanalytical Instruments for Drug Discovery Cell-Based Assays and Reagents for Drug Discovery Proteomics Drug Discovery Tools Genomics Drug Discovery Tools Bioinformatics as a Platform for Drug Discovery Others: Metabolomics, Combinatorial Chemistry, Systems Biology, and Nanotechnology Chapter 4 Disease Overview Etiology Pathogenesis Symptoms Comorbidities Risk Factors Environmental Genetic Epigenetic Alterations Aging Chapter 5 Disease Management and Treatment Diagnosis of Idiopathic Pulmonary Fibrosis Diagnostic Criteria for IPF Treatments for IPF Lifestyle Changes Oxygen Medications Pulmonary Rehabilitation Lung Transplant Chapter 6 Marketed Drugs for Idiopathic Pulmonary Fibrosis Introduction Overview of Products Esbriet Drug Profile Ofev Drug Profile Chapter 7 Product Forecast for Idiopathic Pulmonary Fibrosis Esbriet (Pirfenidone) Ofev (Nintedanib) Chapter 8 Product Pipeline for Idiopathic Pulmonary Fibrosis Product Pipeline for Idiopathic Pulmonary Fibrosis Chapter 9 Appendix: AcronymsList of Tables Table 1 : Idiopathic Pulmonary Fibrosis Drug Sales, by Country, Through 2024 Table 2 : Main Symptoms of Idiopathic Pulmonary Fibrosis Table 3 : Other Symptoms of Idiopathic Pulmonary Fibrosis Table 4 : Key Drugs Marketed for IPF Table 5 : Esbriet Drug Profile Table 6 : Boehringer Ingelheim GmbH: IPF Product Portfolio Table 7 : Roche: IPF Portfolio Table 8 : Roche: IPF Pipeline Portfolio Table 9 : Ofev Drug Profile Table 10 : Sales of Esbriet for IPF, 2018-2024 Table 11 : Number of IDF Patients Using Esbriet, 2018-2024 Table 12 : Sales of Ofev for IPF, 2018-2024 Table 13 : Number of IPF Patients Using Ofev, 2018-2024 Table 14 : Phase III Pipeline Products in Development for IPF Table 15 : Acronyms Used in This ReportList of Figures Figure 1 : Drug Discovery Process Figure 2 : Schematic View of IPF Pathogenesis Figure 3 : Diagnostic Algorithm for IPF Figure 4 : Boehringer Ingelheim GmbH: Annual Revenue, 2015-2019 Figure 5 : Boehringer Ingelheim GmbH: Revenue Shares, by Business Unit, 2019 Figure 6 : Boehringer Ingelheim GmbH: Revenue Shares, by Region, 2019 Figure 7 : Roche: Annual Revenue, 2018 and 2019 Figure 8 : Roche: Revenue Share, by Product Category, 2019
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.Download eBook